Envestnet Asset Management Inc. Has $2.57 Million Position in Twist Bioscience Co. (NASDAQ:TWST)

Envestnet Asset Management Inc. raised its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 53.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 55,194 shares of the company's stock after purchasing an additional 19,340 shares during the quarter. Envestnet Asset Management Inc. owned 0.09% of Twist Bioscience worth $2,565,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Barclays PLC raised its position in shares of Twist Bioscience by 214.8% in the third quarter. Barclays PLC now owns 153,039 shares of the company's stock valued at $6,913,000 after purchasing an additional 104,420 shares during the period. Avanza Fonder AB bought a new position in shares of Twist Bioscience during the 4th quarter valued at $1,059,000. Principal Financial Group Inc. grew its holdings in shares of Twist Bioscience by 67.5% in the third quarter. Principal Financial Group Inc. now owns 205,864 shares of the company's stock worth $9,301,000 after acquiring an additional 82,953 shares during the period. Oddo BHF Asset Management Sas purchased a new position in Twist Bioscience in the third quarter worth about $3,302,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Twist Bioscience by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company's stock worth $269,860,000 after buying an additional 189,791 shares during the last quarter.

Twist Bioscience Trading Down 1.0 %

Shares of TWST stock traded down $0.37 on Thursday, reaching $37.95. 197,610 shares of the stock were exchanged, compared to its average volume of 977,465. The firm has a 50 day moving average of $39.34 and a two-hundred day moving average of $44.18. The stock has a market cap of $2.26 billion, a P/E ratio of -11.23 and a beta of 2.34. Twist Bioscience Co. has a 1-year low of $30.32 and a 1-year high of $60.90. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09. The company had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business's revenue was up 24.1% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.75) earnings per share. On average, research analysts anticipate that Twist Bioscience Co. will post -2.12 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently commented on TWST. JPMorgan Chase & Co. raised their target price on Twist Bioscience from $35.00 to $40.00 and gave the stock an "underweight" rating in a report on Tuesday, February 4th. Guggenheim set a $50.00 price target on shares of Twist Bioscience in a research note on Friday, March 28th. Scotiabank reaffirmed an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Robert W. Baird increased their price target on Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a report on Tuesday, February 4th. Finally, Barclays cut their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, Twist Bioscience has a consensus rating of "Moderate Buy" and a consensus price target of $52.80.

Insider Buying and Selling

In other news, COO Patrick John Finn sold 2,058 shares of the firm's stock in a transaction dated Wednesday, April 23rd. The stock was sold at an average price of $39.99, for a total value of $82,299.42. Following the sale, the chief operating officer now directly owns 265,460 shares of the company's stock, valued at approximately $10,615,745.40. This trade represents a 0.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Emily M. Leproust sold 1,726 shares of Twist Bioscience stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $41.68, for a total value of $71,939.68. Following the sale, the chief executive officer now directly owns 660,966 shares in the company, valued at approximately $27,549,062.88. This trade represents a 0.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 22,432 shares of company stock worth $1,038,170 in the last ninety days. 3.01% of the stock is currently owned by corporate insiders.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.